Tolterodine tartrate | CAS#124937-52-6 | 124937-51-5 | antimuscarinic

Tolterodine tartrate
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326817

CAS#: 124937-52-6 (tartrate)

Description: Tolterodine, also known as PNU-200583E, s an antimuscarinic drug that is used for symptomatic treatment of urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors whereas older antimuscarinic treatments for overactive bladder act more specifically on M3 receptors. Tolterodine, although it acts on all types of receptors, has fewer side effects than oxybutynin (M3 and M1 selective, but more so in the parotid than in the bladder) as tolterodine targets the bladder more than other areas of the body.

Chemical Structure

Tolterodine tartrate

CAS# 124937-52-6 (tartrate)

Instruction

Theoretical Analysis

MedKoo Cat#: 326817
Name: Tolterodine tartrate
CAS#: 124937-52-6 (tartrate)
Chemical Formula: C26H37NO7
Exact Mass: 0.00
Molecular Weight: 475.582
Elemental Analysis: C, 65.66; H, 7.84; N, 2.95; O, 23.55

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 190
10mg	USD 350
25mg	USD 750
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Related CAS #: 124937-51-5 (free base) 124937-52-6 (tartrate)

Synonym: PNU-200583E; PNU 200583E; PNU200583E; Tolterodine tartrate; Detrol LA; Detrusitol.

IUPAC/Chemical Name: (R)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-methylphenol (2R,3R)-2,3-dihydroxysuccinate

InChi Key: TWHNMSJGYKMTRB-KXYUELECSA-N

InChi Code: InChI=1S/C22H31NO.C4H6O6/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24;5-1(3(7)8)2(6)4(9)10/h6-12,15-17,20,24H,13-14H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t20-;1-,2-/m11/s1

SMILES Code: OC1=CC=C(C)C=C1[C@@H](C2=CC=CC=C2)CCN(C(C)C)C(C)C.O=C(O)[C@H](O)[C@@H](O)C(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: related CAS# CAS#124937-51-5 (Tolterodine free base) CAS#124937-52-6 (Tolterodine tartrate)

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 475.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Gacci M, Sebastianelli A, Salvi M, Schiavina R, Brunocilla E, Novara G, De Nunzio C, Tubaro A, Oelke M, Gravas S, Carini M, Serni S. Tolterodine in the Treatment of Male LUTS. Curr Urol Rep. 2015 Sep;16(9):60. doi: 10.1007/s11934-015-0531-9. Review. PubMed PMID: 26149965.

2: Gacci M, Novara G, De Nunzio C, Tubaro A, Schiavina R, Brunocilla E, Sebastianelli A, Salvi M, Oelke M, Gravas S, Carini M, Serni S. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review. BMC Urol. 2014 Oct 27;14:84. doi: 10.1186/1471-2490-14-84. Review. PubMed PMID: 25348235; PubMed Central PMCID: PMC4230346.

3: Medhi B, Mittal N, Bansal D, Prakash A, Sarangi SC, Nirthi B. Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systematic review. Indian J Physiol Pharmacol. 2013 Oct-Dec;57(4):343-53. Review. PubMed PMID: 24968572.

4: Angulo JC, Valpas A, Rejas J, Linden K, Kvasz M, Snedecor SJ. Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland. Clin Drug Investig. 2014 May;34(5):297-307. doi: 10.1007/s40261-014-0178-1. Review. PubMed PMID: 24567280.

5: Elterman DS, Chughtai B, Kaplan SA, Barkin J. Tolterodine for the treatment of urge urinary incontinence. Expert Opin Pharmacother. 2013 Oct;14(14):1987-91. doi: 10.1517/14656566.2013.823158. Epub 2013 Jul 26. Review. PubMed PMID: 23885788.

6: Omotosho T, Chen CC. Update on tolterodine extended-release for treatment of overactive bladder. Open Access J Urol. 2010 Nov 23;2:185-91. doi: 10.2147/OAJU.S7232. Review. PubMed PMID: 24198627; PubMed Central PMCID: PMC3818890.

7: Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem. 2009;16(33):4481-9. Review. PubMed PMID: 19835561.

8: Chung DE, Te AE. Tolterodine extended-release for overactive bladder. Expert Opin Pharmacother. 2009 Sep;10(13):2181-94. doi: 10.1517/14656560903167965. Review. PubMed PMID: 19663610.

9: Ulahannan D, Wagg A. The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly. Clin Interv Aging. 2009;4:191-6. Epub 2009 May 14. Review. PubMed PMID: 19503781; PubMed Central PMCID: PMC2685240.

10: Salvatore S, Serati M, Bolis P. Tolterodine for the treatment of overactive bladder. Expert Opin Pharmacother. 2008 May;9(7):1249-55. doi: 10.1517/14656566.9.7.1249. Review. PubMed PMID: 18422481.

11: Bolge SC, McDonnell DD, Chen A, Wan GJ. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder. Curr Med Res Opin. 2007 Aug;23(8):1903-12. Review. PubMed PMID: 17610806.

12: Kanofsky JA, Nitti VW. Tolterodine for treatment of overactive bladder. Urol Clin North Am. 2006 Nov;33(4):447-53, viii. Review. PubMed PMID: 17011380.

13: Rovner ES. Tolterodine for the treatment of overactive bladder: a review. Expert Opin Pharmacother. 2005 Apr;6(4):653-66. Review. PubMed PMID: 15934891.

14: Garely AD, Burrows L. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults. Drug Saf. 2004;27(13):1043-57. Review. PubMed PMID: 15471509.

15: Abrams P. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. Expert Opin Pharmacother. 2001 Oct;2(10):1685-701. Review. PubMed PMID: 11825311.

16: Wefer J, Truss MC, Jonas U. Tolterodine: an overview. World J Urol. 2001 Nov;19(5):312-8. Review. PubMed PMID: 11760779.

17: Crandall C. Tolterodine: a clinical review. J Womens Health Gend Based Med. 2001 Oct;10(8):735-43. Review. PubMed PMID: 11703885.

18: Nilvebrant L. Clinical experiences with tolterodine. Life Sci. 2001 Apr 27;68(22-23):2549-56. Review. PubMed PMID: 11392625.

19: Clemett D, Jarvis B. Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging. 2001;18(4):277-304. Review. PubMed PMID: 11341475.

20: Ruscin JM, Morgenstern NE. Tolterodine use for symptoms of overactive bladder. Ann Pharmacother. 1999 Oct;33(10):1073-82. Review. PubMed PMID: 10534221.

Your view history

Tolterodine tartrate featured